Ongoing projects

Ongoing Projects
In the field of clinical research, the objective of projects currently under development is not only to improve the prognosis of patients with certain diseases, but also to offer, for the first time, an effective solution to diseases that are currently untreatable. This is also the ultimate goal of genetic studies, whose aim is to provide in-depth analysis of already known genes and identify new genes related to retinal dystrophies.
Investigación clínica

REALE

Evaluation of the effectiveness of aflibercept intravitreous injection (IVT) in clinical practice in non treated patients with Neovascular Age-Related Macular Degeneration.  

Investigación clínica

Holocore FUP

Long-term safety and follow-up study after autologus cultivated limbal stem cells transplantation for restoretion of corneal epithelium in patients with limbal stem deficiency due to ocular burns. 

Investigación clínica

EDOF

Clinica evaluations of the clinical performance of Phakic IOL.      

Investigación clínica

BST- Cordó umbilical

Evaluation of the effectiveness and security of umbilical cord blood eyedrops for the treatment of neurotrophic keratitis.

Investigación clínica

EFOS

Clinical trial to evaluate the effects of Fydrane® and standard topical mydriatics and anaesthetics protocol on ocular surface after cataract surgery.      

Investigación clínica

MYOPRED

Influence of posterior vitreous detachment on retinal detachment after lens surgery in myopic eyes.

Investigación clínica

ENDOART

Prospective, feasibility study to evatuate the safety of the EndoArt for treatment of subjects suffering from corneal edema.

Investigación clínica

LT4020-302

Performance and safety assessment of t4020 combined with standard post-operative therapy versus standard post-operative therapy in managing corneal epithelial defect following epi-off accelerated corneal cross-linking.

Investigación clínica

Helix

A double-masekd study of SYL1001 in patients with moderate to dry eye disease (DED)

Investigación clínica

VIOLET

An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intravitreal injections to subjects with diabetic macular edema (DME)

Investigación clínica

NEUTON

Ensayo fase IV para evaluar la eficacia de aflibercept en pacientes Naïve con edema macular secundario a Oclusión de la vena central de la retina (OVCR) en régimen de tratamiento indiviualizado Treat and extend (TAE).

Investigación básica

Mass sequencing of exomes for the identification of new genes and variants responsible for retinal dystrophies

Retinitis pigmentosa, with a prevalence of 1 in 4,000 people and more than one million sufferers worldwide, is the most common retinal dystrophy. These diseases are neurodegenerative and caused by the death of the photoreceptors and cells of the retinal pigment epithelium.

Investigación básica

Identification of new retinal dystrophy genes and characterisation of genotype/phenotype correlations

Retinal dystrophies (RD) are a heterogeneous group of hereditary diseases that are characterised by the degenerative effect that they have on the photoreceptors and cells of the retinal pigment epithelium.

Investigación básica

Comprehensive analysis of the ABCA4 gene: characterisation of new pathogenic variants

The vast majority of patients with Stargardt disease, as well as half of recessive cone and rod dystrophy cases, have ABCA4 gene mutations.

Investigación clínica

Spectri

Phase III, multicentre, randomised, double-blind, sham-controlled trial to assess the efficacy and safety of lampalizumab administered by intravitreal injection to patients with geographic atrophy secondary to age-related macular degeneration.

Investigación clínica

Premed

Phase IV: Prevention of macular oedema in cataract surgery. PREMED. Non-commercial research.

Investigación clínica

Harrier

Phase III: Two-year, randomised, double-blind, multicentre, two-group trial comparing the efficacy and safety of 6 mg RTH258 compared to aflibercept in subjects with wet age-related macular degeneration.

Investigación clínica

Artemis

Efficacy and safety of slow-release bimatoprost in patients with open-angle glaucoma or ocular hypertension.

Investigación clínica

Azure

Randomised, active-controlled, parallel group, phase III trial on the efficacy, safety and tolerability of 2 mg aflibercept administered with intyravidial injections using two different regimens of treatment for subjects with neovascular age-related macular degeneration.

Investigación clínica

Cedar

Safety and efficacy of abiciparpegol (AGN-150998) in patients with neovascular age-related macular degeneration.

Investigación clínica

PRGF-Endored

Randomised, parallel-group, multicentre, blind to evaluators clinical trial to assess the efficacy and safety of PRGF-Endoret eye drops in patients with stage 2 and 3 neurotrophic keratitis.

Investigación clínica

Biotek-Padciclo

Phase II, multicentre, randomised, double-masked, 4 parallel arms, controlled, 6-month trial designed to evaluate the safety and efficacy of PAD ciclosporin (CsA 0.06% and 0.03%) ophthalmic dispersion administered once daily in combination with lubricant therapy and a 3-month post-treatment safety follow-up in moderate to severe dry eye patients.

Investigación clínica

Atlantic

Phase IV, randomised, double-blind trial with simulated control for the analysis of the efficacy, safety and tolerability of aflibercept intravenous monotherapy compared to aflibercept and concomitant photodynamic therapy in patients with polypodal choroidal vasculopathy.

Investigación clínica

Iris II

Compensation for blindness with the Intelligent Retinal Implant System (IRIS V2) in patients with retinal dystrophy.

Investigación clínica

Holocore

Efficacy and safety of autologous cultivated limbal stem cells transplantation (ACLSCT) for restoration of corneal epithelium in patients with limbal stem cell deficiency.

Investigación clínica

PanOptix

Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00.